Revenue Growth
Revenue for the second quarter of 2025 was $2.7 million, up 26% sequentially.
FDA Clearances
Hyperfine received FDA clearance for two major new technologies, ahead of their planned schedule.
Gross Margin Expansion
Gross margins expanded by approximately 800 basis points sequentially, reaching 49%.
Next-Generation Swoop System Launch
Successful launch of the next-generation Swoop system, featuring transformative image quality, with the first sale completed within 30 days of FDA clearance.
Cash Burn Reduction
Cash burn was reduced by 19% sequentially, excluding financings.
International Expansion
Optive AI software is now available in Canada, Australia, and New Zealand, with plans to launch in Europe by the end of 2025.